China NT Pharma Group Company Limited has issued a clarification regarding its major transaction involving the acquisition of 100% of the issued shares in target companies, which includes the issuance of consideration shares under a specific mandate. The company has corrected the financial figures disclosed in a previous announcement dated April 28, 2025. The figures for the financial information related to the PRC Operating Company for the years ending December 31, 2023, and December 31, 2024, should be reflected in RMB, not thousands of RMB as previously stated. The revised figures show a revenue of RMB 2,437,639 for 2023 and RMB 1,810,151 for 2024, with losses before and after taxation also updated accordingly. Other details of the transaction remain unchanged.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.